RNF182 and lung adenocarcinoma: Next, Bap was prepared and used to treat HBE (normal lung epithelial cells) and A549 (lung adenocarcinoma) cells, and the results showed that treatment of the cells with Bap significantly downregulated mRNA expression of RNF182 in both HBE and A549 cells (Figures 1C, D).